An experimental drug from Cytokinetics (CYTK) failed to improve the lung function of patients with ALS compared to a placebo. The company presented the negative outcome from a mid-stage clinical trial at a neurology conference on Sunday.
This is the second setback for Cytokinetics and its efforts to develop an effective treatment for ALS, a degenerative nerve disorder that is almost always fatal, typically from respiratory failure.
In late 2017, the South San Francisco-based biotech discontinued the development of a predecessor ALS drug due to poor results from a Phase 3 clinical trial.
About the Author Reprints
